Preoperative Medical Evaluation: Primary Care Clearance Guide
Clinical Practice Update — Cardiac Risk Stratification, Testing, and Perioperative Medication Management for Noncardiac Surgery
This is an original clinical education article informed by current guidelines and evidence. See References below for source documents.
- Clinical Focus
- Evidence-based preoperative medical evaluation of adults undergoing elective noncardiac surgery
- Target Audience
- Family physicians, internists, hospitalists, preoperative clinic nurses, surgical teams
- Setting
- Primary care, preoperative assessment clinics, outpatient consultation
- Source Evidence
- •2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation for Noncardiac Surgery
- •Revised Cardiac Risk Index — Lee et al. (Circulation, 1999)
- •ACCP/CHEST Guideline on Perioperative Management of Antithrombotic Therapy (2022)
- •NICE Guideline NG45 — Routine Preoperative Tests for Elective Surgery (2016)
Key Clinical Takeaways
Effective preoperative medical evaluation is not about “clearing” a patient for surgery — it is about identifying modifiable risk, optimising comorbidities, and giving the surgical team a clear perioperative plan. The rules below distil current guidance into a structured workflow for primary care: a focused history and exam, targeted risk scoring, selective testing, and explicit medication and anticoagulation instructions for the day of surgery.
- 1Structure every assessment around three pillars: active conditions, functional capacity, and surgery-specific risk → Framework
- 2Use the Revised Cardiac Risk Index (RCRI) to stratify cardiac risk for every patient undergoing elective noncardiac surgery → Cardiac Risk
- 3Reserve stress testing for patients with poor or unknown functional capacity undergoing elevated-risk surgery with RCRI ≥ 1 → Cardiac Testing
- 4Do not order routine ECGs, chest X-rays, or basic labs for asymptomatic patients undergoing low-risk surgery → Testing
- 5Continue beta-blockers and statins; hold ACE inhibitors and ARBs the morning of surgery → Medications
- 6Do not initiate new beta-blockers within 24 hours of surgery — the POISE trial showed increased stroke and mortality → Medications
- 7Stop direct oral anticoagulants 1–4 days before surgery based on drug, renal function, and bleeding risk → Anticoagulation
- 8Avoid routine bridging of warfarin — the BRIDGE trial showed more bleeding without thromboembolic benefit in most patients → Anticoagulation
- 9Target perioperative glucose 140–180 mg/dL; hold SGLT2 inhibitors 3–4 days before to prevent euglycaemic DKA → Diabetes
- 10Document explicit instructions for every chronic medication in the preoperative note — surgical teams act on what is written → Documentation
Framework for Preoperative Medical Evaluation
A focused preoperative medical evaluation answers three practical questions: Is there an active condition that must be stabilised before surgery? Can the patient tolerate the physiological demand? And what is the surgery-specific risk? Every decision about testing, referral, and optimisation follows from these three answers.
Identify active cardiopulmonary conditions that require stabilisation before elective surgery: unstable angina, decompensated heart failure, significant arrhythmia, severe valvular disease, recent (within 60 days) acute coronary syndrome or stroke, and unstable COPD or asthma. Any of these warrants postponement and referral rather than a clearance letter.
Strong Rec High Evidence ACC/AHA 2014Estimate functional capacity in metabolic equivalents (METs). Ask the patient whether they can climb a flight of stairs, walk on level ground for four blocks at a normal pace, or do light housework without symptoms — these activities correspond to 4 METs, the threshold above which cardiac risk is substantially lower.
Strong Rec Moderate Evidence ACC/AHA 2014Classify the surgery-specific risk. Procedures such as cataract surgery, endoscopy, and minor superficial procedures are low risk (under 1% major cardiac event rate). Intermediate and high-risk surgery (vascular, major intra-abdominal, emergency procedures, prolonged thoracic surgery) require more detailed workup.
Strong Rec High Evidence ACC/AHA 2014Cardiac Risk Stratification in Preoperative Medical Evaluation
Cardiac events account for most serious perioperative morbidity outside major bleeding. The core of preoperative medical evaluation is therefore a structured cardiac risk estimate — not a reflex ECG or stress test.
Calculate the Revised Cardiac Risk Index for every patient undergoing elective noncardiac surgery. The RCRI assigns one point each for high-risk surgery, ischaemic heart disease, congestive heart failure, cerebrovascular disease, insulin-treated diabetes, and creatinine above 2 mg/dL. Event rates rise with total score.
Strong Rec High Evidence Lee 1999 ACC/AHA 2014Proceed directly to surgery in patients with RCRI 0–1 points and good functional capacity (4 METs or more) without additional cardiac testing. The predicted event rate is low enough that further investigation offers no meaningful reduction in risk.
Strong Rec High Evidence ACC/AHA 2014Consider pharmacological stress testing (stress echocardiography or myocardial perfusion imaging) only when RCRI is at least 1 AND functional capacity is poor or unknown AND the result would change management — for example, in a patient who may be a candidate for revascularisation or surgical postponement.
Moderate Rec Moderate Evidence ACC/AHA 2014Do not pursue preoperative revascularisation (PCI or CABG) solely to reduce perioperative cardiac risk. The CARP trial and subsequent evidence show no survival benefit when revascularisation is performed purely for surgery clearance in stable coronary disease.
Against High Evidence ACC/AHA 2014 CARP TrialRCRI Event Rates by Score
| RCRI Score | Approximate 30-Day MACE Risk | Risk Category | Practical Implication |
|---|---|---|---|
| 0 points | < 1% | Low | Proceed; no further cardiac testing |
| 1 point | ~1% | Low-intermediate | Proceed if functional capacity ≥ 4 METs |
| 2 points | ~3–5% | Intermediate | Consider stress test if poor functional capacity |
| ≥ 3 points | > 5% | High | Refer to cardiology; optimise; shared decision-making |
Preoperative Testing: What to Order, What to Skip
The majority of preoperative testing performed in the United States is unnecessary and frequently harmful — incidental findings lead to workups, delays, and occasionally to cancelled surgery without benefit. Match every test to a specific clinical question.
Do not obtain routine preoperative testing — ECG, chest X-ray, CBC, basic metabolic panel, coagulation studies, urinalysis — in asymptomatic patients scheduled for low-risk surgery. These tests rarely change management and drive unnecessary downstream investigation.
Against High Evidence NICE NG45 Choosing WiselyConsider a 12-lead ECG in patients with known cardiovascular disease, significant arrhythmia, or structural heart disease undergoing intermediate- or high-risk surgery. A preoperative ECG is not indicated in asymptomatic patients having low-risk surgery regardless of age.
Moderate Rec Moderate Evidence ACC/AHA 2014Obtain renal function (creatinine, eGFR) and a CBC in patients with known kidney disease, on anticoagulants, on diuretics, or undergoing intermediate or major surgery with anticipated blood loss. Coagulation studies are indicated only when bleeding history or hepatic disease raises concern.
Moderate Rec Moderate Evidence NICE NG45Avoid routine pulmonary function testing, chest X-rays, and arterial blood gases for uncomplicated surgery in asymptomatic patients. Reserve these for patients with acute respiratory symptoms, suspected undiagnosed pulmonary disease, or scheduled major thoracic or lung-resection surgery.
Against Moderate Evidence NICE NG45 Choosing WiselyPerioperative Medication Management
The most practical output of any preoperative assessment is a written medication plan — what to continue, what to hold, and exactly when. Surgical and anaesthetic teams act on what is documented, not on assumptions.
Continue beta-blocker continuation through the day of surgery in patients already on chronic therapy. Abrupt withdrawal is associated with ischaemia and mortality, and restarting within days rarely matches the pharmacological state achieved by steady-state dosing.
Strong Rec High Evidence ACC/AHA 2014Do not initiate a new beta-blocker in the 24 hours before elective surgery. The POISE trial showed that acutely started beta-blockade increased stroke and overall mortality despite a reduction in non-fatal myocardial infarction. If a beta-blocker is indicated on cardiovascular grounds, start it weeks to months beforehand and titrate carefully.
Against High Evidence POISE Trial ACC/AHA 2014Continue statins through the day of surgery in all patients already taking them. Observational and limited randomised evidence suggests that perioperative statin use reduces cardiac complications in vascular surgery and is safe in other settings.
Strong Rec Moderate Evidence ACC/AHA 2014Hold ACE inhibitors and angiotensin receptor blockers on the morning of surgery, particularly when significant fluid shifts or hypotension are anticipated. Continue them uninterrupted only when they are prescribed specifically for heart failure and the patient is euvolaemic.
Moderate Rec Moderate Evidence ACC/AHA 2014Medication Playbook for the Day of Surgery
| Medication Class | Day-of-Surgery Plan | Rationale | Practical Tip |
|---|---|---|---|
| Beta-blockers | Continue | Withdrawal causes ischaemia | Never start within 24h of surgery |
| Statins | Continue | Perioperative cardiac protection | Restart on post-op day 1 if held |
| ACE inhibitors / ARBs | Hold morning dose | Intraoperative hypotension risk | Continue if for stable HF and euvolaemic |
| Calcium channel blockers | Continue | Stable haemodynamics | Brief hypotension usually self-resolves |
| Diuretics | Hold morning dose | Volume and electrolyte risk | Check K+ before surgery if on loop |
| Low-dose aspirin (secondary prevention) | Continue for most | Thrombotic risk usually > bleeding risk | Hold for neurosurgery and posterior-chamber eye surgery |
| NSAIDs | Hold 3–7 days before | Platelet inhibition, renal risk | Offer paracetamol as bridge |
| SSRIs / SNRIs | Continue | Avoid discontinuation syndrome | Note small bleeding risk for major surgery |
Perioperative Anticoagulation Management
Anticoagulation decisions balance thromboembolic risk against perioperative bleeding. The 2022 ACCP/CHEST guideline simplified practice: most patients do not need bridging, and most DOAC interruption is short and predictable.
Stop direct oral anticoagulants based on bleeding risk and renal function. For standard-bleeding-risk procedures, hold apixaban, rivaroxaban, and edoxaban 1 day and dabigatran 1–2 days preoperatively. For high-bleeding-risk procedures, or in chronic kidney disease, DOAC interruption extends to 2–4 days. No bridging is needed during the interval.
Strong Rec High Evidence ACCP/CHEST 2022Hold warfarin approximately 5 days before elective surgery and confirm INR is below 1.5 on the day of the procedure. Restart warfarin within 12–24 hours postoperatively when haemostasis is achieved.
Strong Rec High Evidence ACCP/CHEST 2022Avoid routine heparin bridging for most patients on warfarin. The BRIDGE trial showed that forgoing bridging was non-inferior for thromboembolism and significantly reduced bleeding in atrial fibrillation without mechanical valves. Reserve bridging for very high thromboembolic risk: recent VTE, mechanical mitral valve, older-generation mechanical aortic valve, or stroke within 3 months.
Against High Evidence BRIDGE Trial ACCP/CHEST 2022Continue dual antiplatelet therapy through the first 6 months after a drug-eluting stent unless life-threatening bleeding risk makes interruption unavoidable — and then in close consultation with cardiology. Discontinuation within the high-risk period is associated with catastrophic stent thrombosis.
Strong Rec High Evidence ACC/AHA 2014Perioperative Diabetes Management
Perioperative hyperglycaemia increases infection, delays wound healing, and lengthens hospital stay; perioperative hypoglycaemia is life-threatening. The target range is wider than ambulatory control suggests.
Target perioperative blood glucose 140–180 mg/dL (7.8–10.0 mmol/L) in hospitalised surgical patients. Tighter control does not improve outcomes and increases hypoglycaemia; looser control worsens surgical-site infection and wound healing.
Strong Rec High Evidence ADA Standards Endocrine SocietyHold SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin, ertugliflozin) 3–4 days before elective surgery. Continuation through a fasting, stressed state increases the risk of euglycaemic diabetic ketoacidosis, a diagnostic trap because blood glucose can remain under 200 mg/dL.
Strong Rec Moderate Evidence FDA 2020 ADA StandardsHold oral hypoglycaemic agents and GLP-1 receptor agonists on the morning of surgery. Consider holding GLP-1 agonists 7 days before (weekly formulations) or 1 day (daily formulations) when significant delayed gastric emptying is a concern, in line with recent anaesthesiology guidance.
Moderate Rec Low Evidence ASA 2023Continue basal insulin at 70–80% of the usual dose on the morning of surgery in patients with type 1 diabetes and at 80–100% in type 2 diabetes. Hold short-acting prandial insulin while fasting. Never abruptly stop basal insulin in type 1 diabetes — DKA follows quickly.
Strong Rec Moderate Evidence Endocrine Society ADA StandardsClinical Decision Pathway
A practical, question-based sequence that fits into a 20–30 minute consultation.
Evidence in Context
Where the major guidelines agree, the landmark trials that have shaped practice, and where uncertainty remains.
The POISE Trial and Beta-Blocker Caution
The POISE trial randomised more than 8,000 patients to perioperative metoprolol or placebo and found that fresh beta-blocker initiation reduced non-fatal myocardial infarction but increased stroke and overall mortality. The net harm reshaped global practice: never start a beta-blocker hours before surgery, but continue established therapy faithfully.
The BRIDGE Trial: Warfarin Without Bridging
The BRIDGE trial tested heparin bridging versus placebo in patients with atrial fibrillation on warfarin requiring procedural interruption. No-bridging was non-inferior for arterial thromboembolism while reducing major bleeding by more than half. The trial transformed perioperative anticoagulation from a reflex bridge to a selective one.
Where the Evidence Is Still Moving
GLP-1 receptor agonists and gastric emptying: The 2023 ASA alert on delayed gastric emptying led to widespread hold protocols, although the evidence base remains largely observational.
Biomarkers for risk stratification: Preoperative NT-proBNP and high-sensitivity troponin add prognostic information beyond the RCRI and are being incorporated into updated risk tools — particularly in vascular surgery populations.
Choosing Wisely and low-value testing: The continuing gap between guideline recommendations and observed preoperative test utilisation remains one of the most actionable quality improvement opportunities in ambulatory practice.
Where ACC/AHA and ESC Agree (and Differ)
Both the ACC/AHA and ESC frameworks centre on functional capacity, RCRI-equivalent stratification, and selective testing. ESC guidance places somewhat greater emphasis on NT-proBNP measurement and on formal frailty assessment in older adults, while ACC/AHA retains a stronger emphasis on stepwise algorithmic testing decisions. Either framework, applied consistently, outperforms routine testing.
References
- 1.Fleisher LA, Fleischmann KE, Auerbach AD, et al. 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery. J Am Coll Cardiol. 2014;64(22):e77–e137. doi:10.1016/j.jacc.2014.07.944
- 2.Lee TH, Marcantonio ER, Mangione CM, et al. Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. Circulation. 1999;100(10):1043–1049. doi:10.1161/01.CIR.100.10.1043
- 3.Douketis JD, Spyropoulos AC, Murad MH, et al. Perioperative Management of Antithrombotic Therapy: An American College of Chest Physicians Clinical Practice Guideline. Chest. 2022;162(5):e207–e243. doi:10.1016/j.chest.2022.07.025
- 4.Devereaux PJ, Sessler DI. Cardiac Complications in Patients Undergoing Major Noncardiac Surgery. N Engl J Med. 2015;373(23):2258–2269. doi:10.1056/NEJMra1502824
- 5.NICE Guideline [NG45]. Routine preoperative tests for elective surgery. 2016. nice.org.uk/guidance/ng45
How to Read the Evidence Tags
Every recommendation carries two tags for recommendation strength and evidence quality — Medaptly’s own simplified interpretations.
Recommendation Strength
| Tag | What It Means |
|---|---|
| Strong Rec | High-quality evidence broadly supports this action. |
| Moderate Rec | The weight of evidence favours this action. |
| Conditional Rec | The benefit is less certain — individualise based on patient factors. |
| Against | Evidence shows no benefit or potential harm. |
Evidence Quality
| Tag | What It Means |
|---|---|
| High Evidence | Multiple well-designed RCTs or high-quality meta-analyses. |
| Moderate Evidence | Single RCT or large observational studies. |
| Low Evidence | Expert consensus or small studies. |